By Peter J. Pitts
Imagine you’re diagnosed with a rare cancer. There are no FDA-approved treatments. But after frantically searching the internet, you discover hopeful news — a pharmaceutical company is developing a possible cure.
Unfortunately, the drug is in the early stages of development. It’s not FDA approved — at least not yet. There’s no guarantee the medicine will work. There might even be serious, unknown side effects. But, of course, you’re eager to try it — the alternative is certain death.
The good news is that under current law, you could petition the company for permission to try the experimental drug. If the company agrees, you would then have to seek permission from the FDA.
Some members of Congress believe the FDA should be taken out of the equation. They complain that the agency bogs down the review process and prevents terminally ill patients from accessing potentially lifesaving treatments.
Many physicians already prescribe drugs off-label, since many medicines effectively treat conditions that aren’t listed on the prescribing label. One in five prescriptions is issued for off-label uses.
Current FDA regulations bar manufacturers from promoting the off-label uses of their drugs. As a result, many physicians and patients remain unaware of these uses or are hesitant to try a drug off-label. As a company selling health supplements, you want the opportunity to push your own name, you want your customer’s to know where they have purchased from and hopefully purchase from you time and time again. When you run a business of this nature, you want to ensure you use a reputable supplier that only provides high quality products made from the best raw ingredients. Ideally they will provide you with a private label service, a service that can be valuable to your business. The first advantage of private label supplements is the convenience it provides. You get to enjoy high quality labels printed with your company name and logo and placed directly on the bottles before they are shipped to you. As you can imagine this can save you so much time and money in the long run. You can go to GMPLabeling.
You could print your own labels in your office, but are they going to be of the same high quality that the supplier can provide? Then you need to take the cost of the ink and labels into consideration. If you are trying to make a professional and reputable impression, then you want well designed labels that make a statement. This is also a great marketing opportunity. The more customers that order your private label product, the more people are going to know your company name. A customer boasts to a friend about the weight she has lost using one of your high quality supplements, she grabs the bottle to show the friend and your name is there for all to see. This can also improve sales turnover, get your name out there and improve brand visibility. Private label supplements are designed to help you, as the supplier’s customer, achieve results. It’s a win-win situation for you and your supplier, as you will both benefit as your name is remembered by customers. Now that you have determined your supplier is qualified & scalable let explore products. Reviewing your private label vitamin supplier’s product list will help you to determine that the possibility for line extension is an option. Many companies provide only a small selection of products. In this case as your business grows and you decide to offer more products for your product line you will be restricted by the capabilities of your supplier. Don’t allow your business to be restricted by the qualifications of your vendors. You are only as strong as your weakest link and a private label vitamin or supplement vendor should not be your weakest link.
They recently introduced the Trickett Wendler Right to Try Act of 2017, which would allow “unrestricted possession and use” of experimental drugs. It passed the Senate in early August.
Lawmakers’ hearts are in the right place. But they’re misinformed. The FDA doesn’t delay the process — and cutting out the agency would be dangerous.
When it comes to reviewing patients “expanded access” applications, FDA officials do not drag their feet. From 2012 to 2015, the FDA reviewed nearly 5,800 expanded access requests and authorized 99 percent of them, according to the Government Accountability Office.
The FDA approved emergency requests in less than a day, on average. It generally approves regular requests in four days.
The FDA had good reason to deny the one percent of applications. Some applications were incomplete, others requested drugs that did not demonstrate “efficacy for its intended use” and others asked for medicines to treat diseases for which there were already available treatments.
If the FDA were not required to review these applications, then many patients might find themselves taking experimental drugs that do more harm than good.
The FDA also recently simplified the application process.
Previously, physicians had to provide 26 types of information and complete seven attachments to recommend a patient’s expanded access request.
Filing out sometimes took more than 100 hours. The new application, launched in summer 2016, only asks for eight types of information and one attachment. Physicians can complete it in 45 minutes.
There’s not much room for improvement in the expanded access application process. But there’s still a way for the FDA to increase sick patients’ treatment options.
The agency could encourage doctors to prescribe more medications “off-label.” That means using a drug approved for one disease to treat a different condition.
Allowing drug makers to share truthful, accurate and non-misleading information about off-label uses could help physicians and patients make better treatment decisions.
The FDA already provides patients with safe, quick access to experimental treatments. There’s no reason to cut the agency out of the process.
Lawmakers would better serve vulnerable patients by allowing the FDA to ease off-label prescribing regulations.
Peter J. Pitts, a former FDA associate commissioner, is president of the Center for Medicine in the Public Interest.
